Macular Edema
Conditions
Keywords
Macular Edema, Retinal Vein Occlusion, Dexamethasone Intravitreal Implant
Brief summary
This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). A more durable intravitreal implant containing a low dose of dexamethasone may result in less frequent retreatments, and potentially lower the incidence of steroid-related side effects without compromising efficacy.
Detailed description
AR-1105 is a dexamethasone containing implant drug delivery system that is injected into the back of the eye. It is designed to dissolve slowly over time, continuously releasing a consistent low dose of steroid to treat the symptoms of RVO and associated inflammation with a goal of halting further visual disturbance and damage, and also possibly restoring some vision as symptoms are controlled. In this study, 2 different formulations are being tested to find the optimum combination of efficacy, safety and durability that will offer patients a potential treatment option that is as safe and effective as the treatments currently available, but which requires less frequent injections and potentially has a lower risk for certain side-effects.
Interventions
DRUGAR-1105-CF1
AR-1105 clinical formulation 1 (AR-1105-CF1)
DRUGAR-1105-CF2
AR-1105 clinical formulation 2 (AR-1105-CF2)
Sponsors
Aerie Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single injection of either of 2 formulations of AR-1105 dexamethasone intravitreal implant (CF1 or CF2) administered in a single eye. An initial safety cohort of up-to 5 subjects may be enrolled onto CF1 prior to the randomized phase. During the randomized phase of the study, subjects will be assigned in a 1:1 ratio to either CF1 or CF2. Each subject will complete a 6-month primary evaluation period. Residual implant assessment will be performed by 3-field fundus photography at Day 7 and at Months 3, 4, 5, and 6, and if necessary at monthly visits thereafter until the subject requires retreatment, or until 1 month after the implant is no longer visible, or to Month 9, whichever comes first.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. At least 18 years of age 2. Vision loss due to clinically detectable macular edema (ME) associated with either central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Subjects may be treatment-naïve, or if previously-treated with a steroid, must have demonstrated response to treatment 3. Duration of macular edema (ME) ≥9 months in subjects with CRVO and ≥12 months in subjects with BRVO. If both eyes are eligible, the study eye will be the eye with worse VA 4. Best-corrected visual acuity (BCVA) as measured by the early treatment of diabetic retinopathy study (ETDRS) methodology of between 25 and 70 letters, in the study eye and better than 35 letters, in the non-study eye 5. Retinal thickness in the central subfield of \>290 µm (females) and \>305 μm (males) if using a Cirrus (Zeiss) instrument, or if a Spectralis (Heidelberg) instrument is used, thickness should be \>305 μm (females) or \>320 μm (males) in the study eye 6. Be able to understand and willing to provide written informed consent. 7. Be willing and able to adhere to the instructions set forth in the study protocol
Exclusion criteria
Ophthalmic: 1. Presence of a clinically significant epiretinal membrane, active retinal or optic disc neovascularization, active or history of choroidal neovascularization, presence of rubeosis iridis 2. History or presence of herpetic infection, toxoplasmosis, chorioretinopathy. 3. Subjects with moderate non-proliferative diabetic retinopathy or worse in either eye are excluded from participation 4. Any active infection 5. Aphakia, significant posterior capsule tear or iris trauma in the study eye 6. Anterior-chamber intraocular lens 7. Clinically significant media opacity 8. History of glaucoma or visual field loss 9. Ocular hypertension in the study eye at qualification, (with or without treatment) 10. History of corticosteroid-induced IOP increase in either eye 11. Ocular condition in the study eye that, in the opinion of the investigator, would prevent a 15-letter improvement in visual acuity 12. Received an intraocular steroid injection or implant within 6 months or any anti-VEGF treatment within 2 months prior to screening. Prior treatment with RETISERT® or ILUVIEN® or pan-retinal photocoagulation (PRP) is exclusionary 13. Intraocular surgery (including laser refractive or eyelid surgery) within 3 months prior to Visit 1 or anticipated need for ocular surgery or ophthalmic laser treatment during the study treatment period 14. Currently using topical corticosteroids in the vicinity of the eyes within the 1 month prior to Visit 1 15. Periocular depot of steroids placed within 6 months prior to qualification 16. Ocular medications that are specifically disallowed in this protocol for any condition during the study or within the specified timeframe prior to Visit 2 17. Have progressive optic nerve disease or retinal disease other than retinopathy due to RVO that affects BCVA Systemic: 18. Currently using or anticipating the use of systemic corticosteroids during the study (with the exception of inhaled, intranasal or topical corticosteroids) 19. Any clinically significant or uncontrolled serious or severe medical or psychiatric condition 20. Participation in any other interventional clinical study within 30 days prior to Visit 1 21. History of hypersensitivity or poor tolerance to any components of the preparations to be used in this study such as dexamethasone or biodegradable polymer (PLGA) excipients or fluorescein 22. Systemic condition that may confound the study outcome per the investigator's opinion 23. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety Tolerability: Number of Ocular and Non-ocular TEAEs | Up to 6 months treatment duration | Treatment-emergent adverse events summarized at the subject level by system organ class and preferred term are available in the Adverse Events module. Data reported in the table below corresponds to the total number of participants with ocular and non-ocular treatment-emergent adverse events (TEAEs). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| AR-1105-CF1 Initial Phase Single dose of AR-1105-CF1 (dexamethasone 340 mcg) administered as an intravitreal implant into a single eye | 5 |
| AR-1105-CF1 Randomization Phase Single dose of AR-1105-CF1 (dexamethasone 340 mcg) administered as an intravitreal implant into a single eye | 22 |
| AR-1105-CF2 Randomization Phase Single dose of AR-1105-CF2 (dexamethasone, 340 mcg) administered as an intravitreal implant into a single eye | 22 |
| Total | 49 |
Baseline characteristics
| Characteristic | AR-1105-CF1 Initial Phase | AR-1105-CF1 Randomization Phase | AR-1105-CF2 Randomization Phase | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 12 Participants | 16 Participants | 31 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 10 Participants | 6 Participants | 18 Participants |
| Age, Continuous | 67 Years | 66 Years | 72 Years | 68 Years |
| Race/Ethnicity, Customized Race : American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Race : Asian | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Race : Black or African American | 0 Participants | 2 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Race : Multiple Race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race : Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race : Other | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race : White | 5 Participants | 19 Participants | 19 Participants | 43 Participants |
| Region of Enrollment United States | 5 participants | 22 participants | 22 participants | 49 participants |
| Sex: Female, Male Female | 0 Participants | 9 Participants | 13 Participants | 22 Participants |
| Sex: Female, Male Male | 5 Participants | 13 Participants | 9 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 22 | 0 / 22 |
| other Total, other adverse events | 5 / 5 | 9 / 22 | 11 / 22 |
| serious Total, serious adverse events | 2 / 5 | 2 / 22 | 4 / 22 |
Outcome results
Primary
Safety Tolerability: Number of Ocular and Non-ocular TEAEs
Treatment-emergent adverse events summarized at the subject level by system organ class and preferred term are available in the Adverse Events module. Data reported in the table below corresponds to the total number of participants with ocular and non-ocular treatment-emergent adverse events (TEAEs).
Time frame: Up to 6 months treatment duration
Population: All safety evaluations were conducted on subjects in the safety population. The safety population included all subjects who received study medication. This population was used to summarize safety variables. Subjects were analyzed as-treated
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Initial Phase: AR-1105-CF1 | Safety Tolerability: Number of Ocular and Non-ocular TEAEs | 5 participants |
| Randomization Phase: AR-1105-CF1 | Safety Tolerability: Number of Ocular and Non-ocular TEAEs | 22 participants |
| Randomization Phase: AR-1105-CF2 | Safety Tolerability: Number of Ocular and Non-ocular TEAEs | 22 participants |